FGFR1 and neoplasm: Nintedanib inhibited the growth of tumors formed by FGFR1-amplified NCI-H520 and LK‐2 cells (20); PD173074 shrunk xenografted FGFR1-amplified NCI-H1581 cell tumors; and AZD4547 led to significant tumor growth inhibition (TGI > 94–199%) in four of five FGFR1-amplified patient-derived squamous lung cancer models (47).